重新审视肝细胞癌切除术中的门静脉高压症：超越黑白的风险梯度 - Suppr

Suppr

超能文献

Rethinking portal hypertension in hepatocellular carcinoma resection: a gradient of risk beyond black and white.

作者信息

Pereyra David, Starlinger Patrick

机构信息

Department of General Surgery, Division of Visceral Surgery, Medical University of Vienna, Vienna, Austria.

Department of General Surgery, Division of Transplantation, Medical University of Vienna, Vienna, Austria.

出版信息

Hepatobiliary Surg Nutr. 2025 Jun 1;14(3):490-493. doi: 10.21037/hbsn-2025-213. Epub 2025 May 26.

DOI:10.21037/hbsn-2025-213

PMID:40529933

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12170036/

Abstract

摘要

相似文献

Rethinking portal hypertension in hepatocellular carcinoma resection: a gradient of risk beyond black and white.重新审视肝细胞癌切除术中的门静脉高压症：超越黑白的风险梯度

Hepatobiliary Surg Nutr. 2025 Jun 1;14(3):490-493. doi: 10.21037/hbsn-2025-213. Epub 2025 May 26.

Influence of clinically significant portal hypertension on surgical outcomes and survival following hepatectomy for hepatocellular carcinoma: a systematic review and meta-analysis.临床显著门静脉高压对肝细胞癌肝切除术后手术结局和生存的影响：一项系统评价和荟萃分析

J Hepatobiliary Pancreat Sci. 2014 Sep;21(9):639-47. doi: 10.1002/jhbp.124. Epub 2014 May 27.

Total bile acid is a useful tool for evaluating the risk of portal hypertension in patients with hepatocellular carcinoma who have undergone hepatectomy.总胆汁酸是评估接受肝切除术的肝细胞癌患者门静脉高压风险的有用工具。

Curr Med Res Opin. 2025 Feb;41(2):253-259. doi: 10.1080/03007995.2025.2466720. Epub 2025 Feb 22.

Hepatic resection for hepatocellular carcinoma in patients with portal hypertension: a long-term benefit compared with transarterial chemoembolization and thermal ablation.门静脉高压患者肝细胞癌肝切除术：与经动脉化疗栓塞术和热消融术相比的长期获益

Medicine (Baltimore). 2015 Feb;94(7):e495. doi: 10.1097/MD.0000000000000495.

The Impact of Portal Hypertension Assessment Method on the Outcomes of Hepatocellular Carcinoma Resection: A Meta-Analysis of Matched Cohort and Prospective Studies.门静脉高压评估方法对肝细胞癌切除术结局的影响：一项匹配队列和前瞻性研究的荟萃分析。

Ann Surg. 2024 Jul 1;280(1):46-55. doi: 10.1097/SLA.0000000000006185. Epub 2023 Dec 21.

Transcriptome analysis of mesenteric arterioles changes and its mechanisms in cirrhotic rats with portal hypertension.肝硬化门静脉高压症大鼠肠系膜小动脉转录组分析及其机制。

BMC Genomics. 2023 Jan 14;24(1):20. doi: 10.1186/s12864-023-09125-7.

Liver resection for hepatocellular carcinoma in patients with clinically significant portal hypertension.对具有临床显著门静脉高压症的肝细胞癌患者进行肝切除术。

JHEP Rep. 2020 Oct 8;3(1):100190. doi: 10.1016/j.jhepr.2020.100190. eCollection 2021 Feb.

Hepatic resection is safe and effective for patients with hepatocellular carcinoma and portal hypertension.肝切除术对于肝细胞癌合并门静脉高压症患者而言是安全有效的。

PLoS One. 2014 Sep 30;9(9):e108755. doi: 10.1371/journal.pone.0108755. eCollection 2014.

CPZ: A Highly Sensitive Diagnostic Biomarker for the Differentiation Between Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma, Particularly in Poorly Differentiated Hepatocellular Carcinoma.CPZ：一种用于区分肝细胞癌和肝内胆管癌的高敏诊断生物标志物，尤其适用于低分化肝细胞癌。

Am J Surg Pathol. 2025 Jul 1;49(7):711-729. doi: 10.1097/PAS.0000000000002393. Epub 2025 Apr 7.

Evaluating liver resection outcomes post Y90 TARE with personalized dosimetry in intermediate or advanced hepatocellular carcinoma: a focus on surgical and biliary complications.评估90钇微球肝动脉内放射治疗（TARE）联合个体化剂量测定法治疗中晚期肝细胞癌后的肝切除结果：重点关注手术和胆道并发症

Hepatobiliary Surg Nutr. 2025 Jun 1;14(3):398-410. doi: 10.21037/hbsn-24-151. Epub 2024 Nov 19.

本文引用的文献

Von Willebrand Factor Antigen Improves Risk Stratification for Patients with a Diagnosis of Resectable Hepatocellular Carcinoma.血管性血友病因子抗原可改善可切除肝细胞癌患者的风险分层。

Ann Surg Oncol. 2024 Oct;31(10):6526-6536. doi: 10.1245/s10434-024-15618-w. Epub 2024 Jun 19.

Simple blood tests to diagnose compensated advanced chronic liver disease and stratify the risk of clinically significant portal hypertension.简单的血液检测可用于诊断代偿期晚期慢性肝病并分层预测临床显著门静脉高压风险。

Hepatology. 2024 Oct 1;80(4):887-900. doi: 10.1097/HEP.0000000000000829. Epub 2024 Mar 6.

Prognostic performance of non-invasive tests for portal hypertension is comparable to that of hepatic venous pressure gradient.无创性检测方法对门静脉高压症的预测性能与肝静脉压力梯度相当。

J Hepatol. 2024 May;80(5):744-752. doi: 10.1016/j.jhep.2023.12.028. Epub 2024 Jan 11.

Ann Surg. 2024 Jul 1;280(1):46-55. doi: 10.1097/SLA.0000000000006185. Epub 2023 Dec 21.

Baveno VII - Renewing consensus in portal hypertension.《巴韦诺 VII 共识：门静脉高压领域的新共识》

J Hepatol. 2022 Apr;76(4):959-974. doi: 10.1016/j.jhep.2021.12.022. Epub 2021 Dec 30.

Liver Stiffness Measured by Two-Dimensional Shear Wave Elastography for Predicting Symptomatic Post-hepatectomy Liver Failure in Patients with Hepatocellular Carcinoma.二维剪切波弹性成像测量肝脏硬度以预测肝细胞癌患者肝切除术后症状性肝衰竭

Ann Surg Oncol. 2022 Jan;29(1):327-336. doi: 10.1245/s10434-021-10563-4. Epub 2021 Aug 11.

Noninvasive Diagnosis of Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease.代偿期慢性肝病患者门静脉高压的非侵入性诊断。

Am J Gastroenterol. 2021 Apr;116(4):723-732. doi: 10.14309/ajg.0000000000000994.

Predicting Postoperative Liver Dysfunction Based on Blood-Derived MicroRNA Signatures.基于血液源性 microRNA 特征预测术后肝功能障碍。

Hepatology. 2019 Jun;69(6):2636-2651. doi: 10.1002/hep.30572. Epub 2019 Apr 10.

The predictive value of future liver remnant function after liver resection for HCC in noncirrhotic and cirrhotic patients.肝切除术后非肝硬化和肝硬化患者剩余肝功能的预测价值。

HPB (Oxford). 2019 Jul;21(7):912-922. doi: 10.1016/j.hpb.2018.11.012. Epub 2019 Feb 4.

The macrophage activation marker sCD163 combined with markers of the Enhanced Liver Fibrosis (ELF) score predicts clinically significant portal hypertension in patients with cirrhosis.巨噬细胞活化标志物可溶性CD163（sCD163）与增强肝纤维化（ELF）评分的标志物相结合，可预测肝硬化患者临床上显著的门静脉高压。

Aliment Pharmacol Ther. 2016 Jun;43(11):1222-31. doi: 10.1111/apt.13618. Epub 2016 Apr 7.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验